Skip to main content

Humatin

Generic: PAROMOMYCIN SULFATE

Verified·Apr 23, 2026
Manufacturer
Waylis Therapeutics
NDC
80725-250
RxCUI
207347
Route
ORAL
ICD-10 indication
A06.9

Affordability Check

How much will you actually pay for Humatin?

In 30 seconds, see every legitimate way to afford Humatin — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Humatin

What is this medication? Humatin is an aminoglycoside antibiotic primarily prescribed to treat intestinal amebiasis, an infection caused by a specific type of parasite. Unlike many other antibiotics that are absorbed into the bloodstream, this medication stays within the digestive tract to target and eliminate parasites living in the intestines. It works by interfering with the protein synthesis of the invading organisms, effectively stopping their growth and neutralizing the infection. In addition to treating parasitic infections, Humatin is also used as an adjunctive therapy in the management of hepatic coma. In this context, it helps lower blood ammonia levels by reducing the population of ammonia-producing bacteria in the gut. Because the drug is poorly absorbed by the body, it is generally effective for localized intestinal issues while minimizing systemic side effects, although patients should always follow their healthcare provider's specific dosing instructions.

Copay & patient assistance

  • Patient Copay Amount: Pay as little as $5 per month
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Humatin. Official source: DailyMed (NLM) · Label effective Nov 13, 2025

Indications and usage
INDICATIONS AND USAGE Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Dosage and administration
DOSAGE AND ADMINISTRATION Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days. Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.
Contraindications
CONTRAINDICATIONS Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.
Adverse reactions
ADVERSE REACTIONS Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily. To report SUSPECTED ADVERSE REACTIONS, Waylis Therapeutics LLC at 844-200-7910 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Humatin appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

25%

1,393 of 5,509 plans

Most common tier

Tier 5

On 89% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)8
11%
Tier 5 (specialty)67
89%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 75 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.